The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020
Open accessAbstract
On 5 February 2020, in Yokohama, Japan, a cruise ship hosting 3,711 people underwent a 2-week quarantine after a former passenger was found with COVID-19 post-disembarking. As at 20 February, 634 persons on board tested positive for the causative virus. We conducted statistical modelling to derive the delay-adjusted asymptomatic proportion of infections, along with the infections’ timeline. The estimated asymptomatic proportion was 17.9% (95% credible interval (CrI): 15.5–20.2%). Most infections occurred before the quarantine start.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Cited by
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing
Ferretti, L., Wymant, C., Kendall, M., Zhao, L., Nurtay, A., Abeler-Dörner, L., Parker, M., Bonsall, D., & Fraser, C. (2020) · Science · doi:10.1126/science.abb6936 · Cited by 2,512
Pan, A., Liu, L., Wang, C., Guo, H., Hao, X., Wang, Q., Huang, J., He, N., Yu, H., Lin, X., et al. (2020) · JAMA · doi:10.1001/jama.2020.6130 · Cited by 1,931
Rubin, G. D., Ryerson, C. J., Haramati, L. B., Sverzellati, N., Kanne, J. P., Raoof, S., Schluger, N. W., Volpi, A., Yim, J.-J., Martin, I. B. K., et al. (2020) · Radiology · doi:10.1148/radiol.2020201365 · Cited by 1,101
Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China
Zhang, J., Litvinova, M., Liang, Y., Wang, Y., Wang, W., Zhao, S., Wu, Q., Merler, S., Viboud, C., Vespignani, A., et al. (2020) · Science · doi:10.1126/science.abb8001 · Cited by 1,107
Estimating the burden of SARS-CoV-2 in France
Salje, H., Tran Kiem, C., Lefrancq, N., Courtejoie, N., Bosetti, P., Paireau, J., Andronico, A., Hozé, N., Richet, J., Dubost, C.-L., et al. (2020) · Science · doi:10.1126/science.abc3517 · Cited by 1,038
Levin, A. T., Hanage, W. P., Owusu-Boaitey, N., Cochran, K. B., Walsh, S. P., & Meyerowitz-Katz, G. (2020) · European Journal of Epidemiology · doi:10.1007/s10654-020-00698-1 · Cited by 844
COVID-19 antibody seroprevalence in santa clara county, california
Bendavid, E., Mulaney, B., Sood, N., Shah, S., Bromley-Dulfano, R., Lai, C., Weissberg, Z., Saavedra-Walker, R., Tedrow, J., Bogan, A., et al. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyab010 · Cited by 669
(2020) · doi:10.3138/jammi-2020-0030 · Cited by 664
Evolution and epidemic spread of SARS-CoV-2 in Brazil
Candido, D. S., Claro, I. M., de Jesus, J. G., Souza, W. M., Moreira, F. R. R., Dellicour, S., Mellan, T. A., du Plessis, L., Pereira, R. H. M., Sales, F. C. S., et al. (2020) · Science · doi:10.1126/science.abd2161 · Cited by 573
“Over 18 to 56% of SARS-CoV-2 transmission is from asymptomatic 10 or pre-symptomatic individuals (11-13), complicating epidemiological assessments and public health efforts to curb the pandemic.”
BackgroundSeroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23–May 12, 2020
Havers, F. P., Reed, C., Lim, T., Montgomery, J. M., Klena, J. D., Hall, A. J., Fry, A. M., Cannon, D. L., Chiang, C.-F., Gibbons, A., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.4130 · Cited by 647
Buss, L. F., Prete, C. A., Abrahim, C. M. M., Mendrone, A., Salomon, T., de Almeida-Neto, C., França, R. F. O., Belotti, M. C., Carvalho, M. P. S. S., Costa, A. G., et al. (2021) · Science · doi:10.1126/science.abe9728 · Cited by 488
Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19
Gostic, K., Gomez, A. C., Mummah, R. O., Kucharski, A. J., & Lloyd-Smith, J. O. (2020) · eLife · doi:10.7554/elife.55570 · Cited by 417
Face mask use in the general population and optimal resource allocation during the COVID-19 pandemic
Worby, C. J., & Chang, H.-H. (2020) · Nature Communications · doi:10.1038/s41467-020-17922-x · Cited by 379
Diop, B. Z., Ngom, M., Pougué Biyong, C., & Pougué Biyong, J. N. (2020) · BMJ Global Health · doi:10.1136/bmjgh-2020-002699 · Cited by 207
Thrombotic complications of COVID-19
Avila, J., Long, B., Holladay, D., & Gottlieb, M. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2020.09.065 · Cited by 143
Digital proximity tracing on empirical contact networks for pandemic control
(2021) · doi:10.1038/s41467-021-21809-w · Cited by 123
Under-reporting of deaths limits our understanding of true burden of covid-19
Whittaker, C., Walker, P. G. T., Alhaffar, M., Hamlet, A., Djaafara, B. A., Ghani, A., Ferguson, N., Dahab, M., Checchi, F., & Watson, O. J. (2021) · BMJ · doi:10.1136/bmj.n2239 · Cited by 122
The origin and early spread of SARS-CoV-2 in Europe
Nadeau, S. A., Vaughan, T. G., Scire, J., Huisman, J. S., & Stadler, T. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012008118 · Cited by 93
Basavaraju, S. V., Patton, M. E., Grimm, K., Rasheed, M. A. U., Lester, S., Mills, L., Stumpf, M., Freeman, B., Tamin, A., Harcourt, J., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1785 · Cited by 110
Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil
Amorim Filho, L., Szwarcwald, C. L., Mateos, S. D. O. G., Ponce de Leon, A. C. M., Medronho, R. D. A., Veloso, V. G., Lopes, J. I. F., Porto, L. C. D. M. S., Chieppe, A., & Werneck, G. L. (2020) · Revista de Saúde Pública · doi:10.11606/s1518-8787.2020054002643 · Cited by 90
Lu, F. S., Nguyen, A. T., Link, N. B., Davis, J. T., Chinazzi, M., Xiong, X., Vespignani, A., Lipsitch, M., & Santillana, M. (2020) · doi:10.1101/2020.04.18.20070821 · Cited by 87
“In addition, it has been estimated that 18% [6] to 50% [7, 8] of people infected with COVID-19 do not show symptoms.”
Jiang, C., Wang, Y., Hu, M., Wen, L., Wen, C., Wang, Y., Zhu, W., Tai, S., Jiang, Z., Xiao, K., et al. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1182 · Cited by 72
Lafon, E., Diem, G., Witting, C., Zaderer, V., Bellmann-Weiler, R. M., Reindl, M., Bauer, A., Griesmacher, A., Fux, V., Hoermann, G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.684014 · Cited by 46
Heterogeneous interventions reduce the spread of COVID-19 in simulations on real mobility data
Wang, H., Ghosh, A., Ding, J., Sarkar, R., & Gao, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-87034-z · Cited by 28
Gazit, S., Mizrahi, B., Kalkstein, N., Neuberger, A., Peretz, A., Mizrahi-Reuveni, M., Ben-Tov, A., & Patalon, T. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab973 · Cited by 24
Beyond dexamethasone, emerging immuno‐thrombotic therapies for COVID‐19
Jensen, M. P., George, M., Gilroy, D., & Sofat, R. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14540 · Cited by 17
Ali, M. A., & Caetano-Anollés, G. (2024) · Viruses · doi:10.3390/v16091358 · Cited by 6
“The Coronavirus Disease 19 ( COVID-19 COVID-19) pandemic has led to a total of 775 , Viruses 2024 , 16 , 1358 2 of 20 experienced 641 COVID-19 infections out of 3711 passengers, with over half (328) of those infected being asymptomatic [11].”
Background
Metadata
- Authors
- Mizumoto, K., Kagaya, K., Zarebski, A., & Chowell, G.
- Venue
- Eurosurveillance
- Published
- 2020-03-12
- Volume
- 25
- Issue
- 10
- ISSN
- 1025-496X (ISSN-L)
- 1560-7917
- OpenAlex
- W3010781325
- Cited by
- 2,276
- References
- 1
- FWCI
- 83.91
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
